Nrx Pharmaceuticals, INC. (NRXPW) — 8-K Filings

All 8-K filings from Nrx Pharmaceuticals, INC.. Browse 40 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (40)

NRX Pharmaceuticals Files 8-K — Dec 29, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on December 29, 2025, reporting an event on December 18, 2025. The filing indicates the company's incorporation in Delawa
8-K Filing — Nov 26, 2025
NRX Pharmaceuticals Files 8-K — Oct 23, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on October 23, 2025, reporting events as of October 17, 2025. The filing includes information related to Regulation FD Di
NRX Pharmaceuticals Files 8-K — Sep 26, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on September 26, 2025, reporting on events that occurred on September 24, 2025. The filing primarily concerns financial s
NRX Pharmaceuticals Completes Asset Acquisition/Disposition — Sep 12, 2025 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on September 12, 2025, reporting the completion of an acquisition or disposition of assets on September 8, 2025. The fili
NRX Pharmaceuticals Files 8-K with Financials — Sep 8, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on September 8, 2025, reporting on events that occurred on September 2, 2025. The filing includes financial statements an
NRX Pharmaceuticals Files 8-K — Aug 15, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on August 15, 2025, reporting on events that occurred on August 11, 2025. The filing primarily concerns financial stateme
NRX Pharmaceuticals Files 8-K Report — Jun 9, 2025 Risk: low
On June 5, 2025, NRX Pharmaceuticals, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as Big Rock Partners
NRX Pharmaceuticals Files 8-K on Financials — May 21, 2025 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on May 21, 2025, reporting on events as of May 15, 2025. The filing pertains to Results of Operations and Financial Condi
NRX Pharmaceuticals Files 8-K — May 13, 2025 Risk: low
On May 13, 2025, NRX Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. The company was fo
NRX Pharmaceuticals Files 8-K — Apr 17, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on April 17, 2025, reporting other events and financial statements. The company, formerly known as Big Rock Partners Acqu
NRX Pharmaceuticals Files 8-K on Financials — Mar 21, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on March 21, 2025, reporting on results of operations, financial condition, and Regulation FD disclosures as of March 17,
NRX Pharmaceuticals Files 8-K — Feb 3, 2025 Risk: medium
On January 28, 2025, NRX Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statemen
NRX Pharmaceuticals Files 8-K: Agreements & Equity Sales — Jan 29, 2025 Risk: medium
NRX Pharmaceuticals, Inc. entered into a material definitive agreement on January 27, 2025, related to the creation of a direct financial obligation. The compan
NRX Pharmaceuticals Files 8-K on Officer/Director Changes — Jan 22, 2025 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on January 22, 2025, reporting events as of January 15, 2025. The filing pertains to the departure of directors or certai
NRX Pharmaceuticals Appoints New CMO, Elects Directors — Jan 14, 2025 Risk: medium
NRX Pharmaceuticals, Inc. announced on January 7, 2025, a significant change in its board of directors and executive compensation. The company appointed Dr. Jon
NRX Pharmaceuticals Files 8-K for Equity Sales — Jan 10, 2025 Risk: medium
NRX Pharmaceuticals, Inc. entered into a material definitive agreement on January 6, 2025, related to unregistered sales of equity securities. The company, form
NRX Pharmaceuticals Appoints Dr. Javitt CEO, Chairman — Nov 20, 2024 Risk: medium
NRX Pharmaceuticals, Inc. announced on November 18, 2024, the appointment of Dr. Jonathan Javitt as Chief Executive Officer and Chairman of the Board. Dr. Javit
NRX Pharmaceuticals Files 8-K on Financials — Nov 15, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on November 15, 2024, reporting on its financial condition and results of operations as of November 14, 2024. The filing
NRX Pharmaceuticals Files 8-K — Oct 31, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on October 31, 2024, reporting other events and financial statements. The company, formerly known as Big Rock Partners Ac
NRX Pharma Files 8-K on Financial Obligations & Equity Sales — Oct 15, 2024 Risk: medium
NRX Pharmaceuticals, Inc. entered into a material definitive agreement on October 10, 2024, related to the creation of a direct financial obligation. The compan
NRX Pharmaceuticals Files 8-K on Corporate Governance Changes — Oct 11, 2024 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on October 11, 2024, reporting on several key events that occurred on October 7, 2024. These include the departure of dir
NRX Pharmaceuticals Board Changes and Officer Compensation — Aug 20, 2024 Risk: medium
NRX Pharmaceuticals, Inc. announced on August 14, 2024, a change in its board of directors. Specifically, Dr. Jonathan Rothbard resigned from the Board of Direc
NRX Pharmaceuticals Files 8-K on Financials — Aug 15, 2024 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition as of August 14, 2024. The filing incl
NRX Pharmaceuticals Faces Delisting Concerns — Aug 12, 2024 Risk: high
NRX Pharmaceuticals, Inc. filed an 8-K on August 12, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was forme
NRX Pharmaceuticals Terminates Material Agreement — Jun 27, 2024 Risk: medium
NRX Pharmaceuticals, Inc. announced the termination of a material definitive agreement on June 21, 2024. The company also reported other events on the same date
NRX Pharmaceuticals Reports Director/Officer Changes & Financials — Jun 20, 2024 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on June 20, 2024, reporting changes effective June 13, 2024. The filing pertains to the departure of directors or certain
NRX Pharmaceuticals Closes $10M Convertible Note Offering — May 23, 2024 Risk: medium
On May 21, 2024, NRX Pharmaceuticals, Inc. filed an 8-K report detailing the completion of a private placement of convertible notes. The company issued $10.0 mi
NRX Pharmaceuticals Files 8-K — May 16, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on May 16, 2024, reporting on events as of May 14, 2024. The filing includes information on results of operations, financ
NRX Pharmaceuticals Files 8-K on Financial Obligations — Apr 30, 2024 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on April 30, 2024, reporting on events that occurred on April 24, 2024. The filing indicates a triggering event related t
NRX Pharmaceuticals Enters Material Definitive Agreement — Apr 19, 2024 Risk: medium
NRX Pharmaceuticals, Inc. entered into a material definitive agreement on April 17, 2024. The company, formerly known as Big Rock Partners Acquisition Corp., is
NRX Pharmaceuticals Files 8-K — Apr 15, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on April 15, 2024, reporting other events and financial statements. The company, formerly known as Big Rock Partners Acqu
NRX Pharmaceuticals Files 8-K on Financials — Apr 2, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on April 2, 2024, reporting on its results of operations and financial condition as of April 1, 2024. The filing includes
NRX Pharmaceuticals Files 8-K on Security Holder Rights — Mar 28, 2024 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on March 28, 2024, to report material modifications to security holder rights and amendments to its articles of incorpora
NRX Pharmaceuticals Files 8-K — Mar 21, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on March 21, 2024, reporting on the submission of matters to a vote of security holders, Regulation FD disclosures, and f
NRX Pharmaceuticals Files 8-K — Mar 6, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on March 5, 2024, reporting other events and financial statements. The company, formerly known as Big Rock Partners Acqui
NRX Pharma Sells Equity, Warrants in Unregistered Offering — Feb 28, 2024 Risk: medium
NRX Pharmaceuticals, Inc. entered into a Material Definitive Agreement on February 27, 2024, involving the unregistered sale of equity securities. This 8-K fili
NRX Pharma Reports Undisclosed Material Agreement — Feb 14, 2024 Risk: medium
NRX Pharmaceuticals, Inc. (CIK: 0001719406) filed an 8-K on February 14, 2024, reporting an "Entry into a Material Definitive Agreement" on February 7, 2024. Th
NRXP Faces Nasdaq Delisting for Bid Price Non-Compliance — Feb 2, 2024
NRX Pharmaceuticals, Inc. (NRXP) announced on February 1, 2024, that it received a notice from the Nasdaq Stock Market regarding its failure to meet the minimum
NRX Pharmaceuticals Faces Delisting Threat, Files 8-K — Jan 23, 2024
NRX Pharmaceuticals, Inc. filed an 8-K on January 23, 2024, reporting an event on January 16, 2024, related to a Notice of Delisting or Failure to Satisfy a Con

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX